Storm et al. used a synthetic anti-RSPO3 mAb to treat PTPRK-RSPO3 fusion-positive CRC cells in PDX mouse models, which effectively inhibited tumor growth and promoted tumor differentiation. This evidence concerns the gene RSPO3 and neoplasm.